Glaucoma Trial, Recruiting NCT05275738 Sponsor: Umeå University Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT05275738
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

General criteria across both parts of the trial:

  • Adults aged 18 or older who have been diagnosed with a specific type of glaucoma (called primary open-angle glaucoma or pseudoexfoliation glaucoma)
  • People whose vision is at a certain minimum level (good enough to read a standard eye chart at a reasonable distance)
  • People who have completed at least two reliable visual field tests (tests that map what a person can see across their full field of vision), with results meeting specific accuracy standards

Additional criteria for one part of the trial (SGNT):

  • People who have been newly diagnosed and have not yet received any treatment for glaucoma in one or both eyes
  • People whose glaucoma diagnosis is confirmed by specific changes to the optic nerve and/or vision

Additional criteria for the other part of the trial (VBIGS):

  • People who already have a confirmed diagnosis of treated glaucoma (including normal tension glaucoma or pseudoexfoliation glaucoma) in both eyes
  • People whose visual field loss falls within a moderate range (between -3 and -18 dB on testing)
  • People who have had a certain type of laser eye treatment (selective laser trabeculoplasty) may still be eligible, provided it was performed 3 or more months before joining and liver function tests are normal
  • People already taking a supplement called NAM may still be considered, but would need to stop taking it for one month before the study begins

Who may not be able to join:

For the SGNT part:

  • People whose vision field damage is beyond a certain level of severity in either eye, or who have a specific type of deep blind spot in any eye
  • People whose eye pressure is above a certain high level
  • People who are pregnant or breastfeeding
  • People who are not willing to avoid taking NAM (nicotinamide) supplements during the trial
  • People who are allergic to NAM or niacin
  • People who have been diagnosed with cancer in the past 5 years (except for certain treated skin cancers)
  • People with a history of liver disease or stomach ulcers
  • People with a condition that would prevent them from attending long-term follow-up appointments
  • People with neurological or other non-glaucoma conditions (other than cataracts) that could affect visual field test results
  • People who are unable to understand and speak Swedish or English
  • People who have had eye surgery (other than uncomplicated cataract surgery)
  • People with conditions known to affect the retina, such as more than mild age-related macular degeneration or more than early-stage diabetic eye disease

For the VBIGS part:

  • People with a history of liver disease or gout
  • People with cataracts that significantly affect vision
  • People with other conditions that could affect visual field test results
  • People who have had cataract surgery in the last 3 months
  • People who have had glaucoma drainage surgery in the last 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +46907850000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Umeå University
Registry
ClinicalTrials.gov
Start date
18 May 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Visual field progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov